Drugs /

ff-10501-01

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable inhibitor of inosine 5'- monophosphate dehydrogenase (IMPDH), with potential antineoplastic activity. Upon administration, IMPDH inhibitor FF-10501-01 competitively inhibits the enzyme IMPDH, thereby preventing the conversion of inosine monophosphate to xanthosine monophosphate. This inhibits the synthesis of guanine nucleotides, deprives cancer cells of guanosine triphosphate (GTP), disrupts DNA and RNA synthesis, and decreases tumor cell proliferation. Tumor cells are highly susceptible to IMPDH inhibition because they are rapidly dividing cells that are dependent on rapid DNA synthesis, which requires a high concentration of nucleotides. IMPDH, an enzyme that catalyzes the rate-limiting step in the synthesis of guanosine triphosphate (GTP), is overexpressed in numerous tumor cell types.

Clinical Trials

View Clinical Trials for ff-10501-01

Ff-10501-01 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating ff-10501-01, 1 is phase 1/phase 2 (0 open).

Complex karyotype, Loss of Y, and Monosomy 7 are the most frequent biomarker inclusion criteria for ff-10501-01 clinical trials.

Acute myeloid leukemia, chronic myelomonocytic leukemia, and myelodysplastic syndromes are the most common diseases being investigated in ff-10501-01 clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Ff-10501-01
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ff-10501-01 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
inosine 5'- monophosphate dehydrogenase inhibitor ff-10501-01, impdh inhibitor ff-10501, inosine 5'-monophosphate dehydrogenase inhibitor ff-10501-01, ff-10501, impdh inhibitor ff-10501
Drug Target(s) [2]:
IMPDH1, IMPDH2
NCIT ID [1]:
C122835

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.